Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
Immunotherapy offers a distinctive mechanism of action compared to traditional treatments, arising from additional value dimensions that may not be captured in standard health technology assessments. Cancer patients may have the expectation that immunotherapy provides durable, long-term survival gai...
Main Authors: | Remziye Zaim, W. Ken Redekop, Carin A. Uyl-de Groot |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1027659/full |
Similar Items
-
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
by: Uiju Cho, et al.
Published: (2024-03-01) -
Effect of Gender on Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Real-World Study
by: Teresa Calleja-Chucla, et al.
Published: (2025-02-01) -
Opportunities and challenges of immune checkpoint inhibitors for extensive‐stage small‐cell lung cancer
by: Jing Zhao, et al.
Published: (2022-08-01) -
Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients
by: Xinyue Wang, et al.
Published: (2024-02-01) -
Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Jie Zhao, et al.
Published: (2024-05-01)